Gynica is a femtech company leading in the clinical development of cannabinoid-based therapeutic solutions to treat gynecological conditions and improve women’s quality of life. We aim to provide evidence-based products that use an innovative local approach to effectively address undertreated gynecological conditions, such as painful menstruation and painful sexual intercourse, with no side effects. Why? 1. Women’s health is experiencing a tidal wave of innovation, as both patients and physicians are looking for solutions that will specifically address women’s health, tailor-made to women’s biology. 2. Second only to the brain, the female reproductive system has the highest percentage of Anandamide endocannabinoid receptors, creating a potential special effect on women’s health. We have made it our mission to develop new formulations, drug delivery methods, and technologies that will focus on utilizing this connection to provide effective medical products to women. As of today, we are the only company in Israel licensed to research the connection between cannabis and women’s health. Gynica is led by world-renowned opinion leaders in gynecology, cannabinoids, and pharmacology. Our Board of Directors is Chaired by Prof. Moshe Hod, a leading expert in the field of women’s health and the President of the European Association of Perinatal Medicine (EAPM). Our Scientific Committee is led by award-winner Prof. Lumir Ondrej Hanuš – the one behind the ground-breaking discovery of the endocannabinoid system, paving the way for decades of research into medical cannabis use. Gynica was founded in 2017 and our HQ is in Tel Aviv.